Harnessing traditional medicine and biomarker-driven approaches to counteract Trichostatin A-induced esophageal cancer progression

doi:10.3748/wjg.v31.i20.106443

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (36)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=33

May 28, 2025 (publication date) through May 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. May 28, 2025; 31(20): 106443
Published online May 28, 2025. doi: 10.3748/wjg.v31.i20.106443

Harnessing traditional medicine and biomarker-driven approaches to counteract Trichostatin A-induced esophageal cancer progression

Heng-Rui Liu

Heng-Rui Liu, Cancer Research Institute, Jinan University, Guangzhou 518000, Guangdong Province, China

Author contributions: Liu HR finished the paper.

Conflict-of-interest statement: There is no conflict of interest.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Heng-Rui Liu, PhD, Cancer Research Institute, Jinan University, Zhongshan Second Road, Yuexiu District, Guangzhou 518000, Guangdong Province, China. lh@yinuobiomedical.cn

Received: February 26, 2025
Revised: March 14, 2025
Accepted: April 11, 2025
Published online: May 28, 2025
Processing time: 91 Days and 8.6 Hours

Core Tip

Core Tip: Trichostatin A, a histone deacetylase inhibitor (HDACi), paradoxically promotes esophageal squamous cell carcinoma (ESCC) progression via the BRD4/c-Myc/endoplasmic reticulum stress pathway. Traditional medicine-derived compounds like berberine, curcumin, and resveratrol may counteract these oncogenic effects by modulating epigenetic regulators. Additionally, histone acetylation markers, particularly acetylated histone H3, hold promise as predictive biomarkers for ESCC progression and HDACi therapy response. Integrating biomarker-driven approaches with natural compounds may enhance ESCC treatment efficacy while mitigating HDACi-associated risks.